Sana Biotechnology (NASDAQ:SANA) Sets New 12-Month Low - Should You Sell?

Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) reached a new 52-week low during trading on Monday . The stock traded as low as $2.35 and last traded at $2.42, with a volume of 227929 shares traded. The stock had previously closed at $2.42.

Analyst Ratings Changes

Several research analysts have commented on SANA shares. JMP Securities cut shares of Sana Biotechnology from an "outperform" rating to a "market perform" rating in a research report on Tuesday, November 5th. Citigroup upped their price target on shares of Sana Biotechnology from $8.00 to $15.00 and gave the company a "buy" rating in a research report on Friday, August 9th. Finally, HC Wainwright restated a "buy" rating and issued a $8.00 price target on shares of Sana Biotechnology in a research report on Monday, November 11th.

Sana Biotechnology Stock Performance

The company's 50 day moving average price is $3.92 and its 200 day moving average price is $5.54. The company has a market cap of $522.45 million, a price-to-earnings ratio of -1.76 and a beta of 1.44.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.01. On average, equities research analysts forecast that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Insider Transactions at Sana Biotechnology

In other Sana Biotechnology news, Director Richard Mulligan sold 150,000 shares of the firm's stock in a transaction dated Tuesday, September 24th. The shares were sold at an average price of $4.08, for a total value of $612,000.00. Following the completion of the sale, the director now owns 2,848,121 shares in the company, valued at approximately $11,620,333.68. This trade represents a 5.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 31.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Sana Biotechnology

Several institutional investors have recently modified their holdings of SANA. Stifel Financial Corp acquired a new stake in shares of Sana Biotechnology during the 3rd quarter worth approximately $43,000. EP Wealth Advisors LLC bought a new position in Sana Biotechnology in the third quarter valued at approximately $45,000. Blue Trust Inc. lifted its stake in Sana Biotechnology by 1,246.6% in the third quarter. Blue Trust Inc. now owns 13,129 shares of the company's stock valued at $55,000 after buying an additional 12,154 shares in the last quarter. Cornercap Investment Counsel Inc. bought a new position in Sana Biotechnology in the third quarter valued at approximately $67,000. Finally, Algert Global LLC bought a new position in Sana Biotechnology in the second quarter valued at approximately $73,000. Institutional investors and hedge funds own 88.23% of the company's stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.